Therapeutic Glaucoma

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Goniotomy-viscodilation cataract surgery controls IOP without medications.

Innovation, change has dominated the glaucoma specialty over the years.

Programs use detection and treatment to ease burden of eye disease.

Sustained release helps mitigate disease progression without impacting quality of life.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

Evidence-based medicine can lead to personalized care, better results for patients

Options can reduce the treatment burden for patients, leading to improved outcomes

Investigators note the need for less medication over 12-month period

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

Besides traditional medications, here are some of the many novel approaches to treat patients with glaucoma

Research is seeking benefits, options for open-angle glaucoma patients

Treatment options may expand beyond surgery, medication, and lasers